690660-17-4
690660-17-4
Chemical Structure
MLN3897
- CAS. Nr.: 690660-17-4
- Formula:C30H31ClN2O4
- Molecular Weight:519.03
InChIKey: NVBMQDQKIKYLDW-WXTRKPKDSA-N
SMILES: CC(C)([C@](CC1)(C2=CC=C(C=C2)Cl)O)CN1CC/C=C3C4=CC(C(O)=O)=CC=C4OCC5=NC=CC=C5/3
Biological Activity: MLN3897 is an orally active CCR1 antagonist. MLN3897 inhibits the c-fos and Akt pathways by blocking the binding of CCL3 to CCR1, thereby reducing immune cell infiltration, attenuating osteoclasts, and interfering with tumor-microenvironment interactions. MLN3897 can be used in research on multiple myeloma, multiple myeloma bone disease, and rheumatoid arthritis[1][2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
MLN3897 | MLN3897 is an orally active CCR1 antagonist. MLN3897 inhibits the c-fos and Akt pathways by blocking the binding of CCL3 to CCR1, thereby reducing immune cell infiltration, attenuating osteoclasts, and interfering with tumor-microenvironment interactions. MLN3897 can be used in research on multiple myeloma, multiple myeloma bone disease, and rheumatoid arthritis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Vallet S, et al. CCR1 as a target for multiple myeloma. Expert opinion on therapeutic targets. 2011 Sep;15(9):1037-47. [Content Brief]
- [2]. Dairaghi DJ, et al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. Clinical pharmacology and therapeutics. 2011 May;89(5):726-34. [Content Brief]
- [3]. Giuliani N, et al. Myeloma and osteoclast relationship. In: Heymann D, editor. Bone Cancer: Primary Bone Cancers and Bone Metastases. 2nd ed. Amsterdam: Academic Press; 2015. p. 491-500.
- [4]. Merritt JR, et al. CCR1. In: Levin JI, Laufer S, editors. Anti-Inflammatory Drug Discovery. Cambridge: Royal Society of Chemistry; 2012. p. 329.
